Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study

被引:1
作者
Wei, Yu-Ce [1 ]
Liu, Wei-Xin [2 ]
Qi, Fei [3 ]
Zhang, Chang-Gong [1 ]
Zheng, Bao-Min [2 ]
Xie, Yan [3 ]
Chen, Bo [4 ]
Zhang, Di [1 ]
Liu, Wei-Ping [3 ]
Fang, Hui [4 ]
Chai, Yue [1 ]
Qi, Shu-Nan [4 ]
Li, Ye-Xiong [4 ]
Wang, Wei-Hu [2 ]
Song, Yu-Qin [3 ]
Zhu, Jun [3 ]
Dong, Mei [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, 52 Fucheng Rd, Beijing 100142, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Radiat Oncol, Beijing, Peoples R China
关键词
Advanced-stage extranodal natural killer/T-cell lymphoma; Non-nasal type; Clinical characteristics; Prognosis; Therapeutics; NON-HODGKIN-LYMPHOMA; KI-67; EXPRESSION; SURVIVAL; SMILE; CHEMOTHERAPY; MULTICENTER; NEOPLASMS; MODEL; INDEX;
D O I
10.1007/s00277-023-05455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study aimed to investigate the clinical features, prognosis, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma (ENKTCL). This real-world study retrospectively reviewed 56 newly diagnosed advanced-stage non-nasal type ENKTCL patients from two large-scale Chinese cancer centers in the last 10-15 years and screened 139 newly diagnosed advanced-stage nasal type ENKTCLs admitted during the same period for comparison. The non-nasal type ENKTCLs exhibited significantly higher Ki-67 expression levels compared to nasal type disease (P = 0.011). With a median follow-up duration of 75.03 months, the non-nasal group showed slightly inferior survival outcomes without statistically significant differences compared to the nasal group (median overall survival (OS): 14.57 vs. 21.53 months, 5-year OS: 28.0% vs. 38.5%, P = 0.120). Eastern Cooperative Oncology Group (ECOG) score >= 2 (hazard ratio (HR) = 2.18, P = 0.039) and lactic dehydrogenase (LDH) elevation (HR = 2.44, P = 0.012) were significantly correlated with worse OS in the non-nasal group. First-line gemcitabine-based chemotherapy regimens showed a trend toward slightly improved efficacy and survival outcomes compared to non-gemcitabine-based ones in the present cohort of non-nasal ENKTCLs (objective response rate: 91.7% vs. 63.6%, P = 0.144; complete response rate: 50.0% vs. 33.3%, P = 0.502; median progression-free survival: 10.43 vs. 3.40 months, P = 0.106; median OS: 25.13 vs. 9.30 months, P = 0.125), which requires further validation in larger sample size studies. Advanced-stage non-nasal type patients could achieve comparable prognosis with nasal cases after rational therapy. The modified nomogram-revised index (including age, ECOG score, and LDH) and modified international prognostic index (including age, ECOG score, LDH, and number of extranodal involvement) functioned effectively for prognostic stratification in non-nasal type ENKTCLs.
引用
收藏
页码:163 / 174
页数:12
相关论文
共 50 条
  • [41] The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
    Zhang, Lei
    Li, Sucai
    Jia, Sisi
    Nan, Feifei
    Li, Zhaoming
    Cao, Jingyu
    Fan, Shanshan
    Zhang, Chao
    Su, Liping
    Wang, Jinghua
    Xue, Hongwei
    Zhang, Mingzhi
    ONCOTARGET, 2016, 7 (36) : 58396 - 58404
  • [42] Real-World clinical features and survival outcomes associated with primary gastrointestinal natural killer/T-cell lymphoma from 1999 to 2020
    Yang Chunli
    Jiang Ming
    Ma Ziyan
    Ji Jie
    Lv Shuli
    Huang Jie
    Wu Yu
    Xu Caigang
    Zou Liqun
    CANCER MEDICINE, 2023, 12 (03): : 2614 - 2623
  • [43] Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
    Liu, Yao-Chung
    Lin, Ting-An
    Wang, Hao-Yuan
    Ko, Po-Shen
    Liu, Chia-Jen
    Hsiao, Liang-Tsai
    Chien, Sheng-Hsuan
    Gau, Jyh-Pyng
    JOURNAL OF MEDICAL CASE REPORTS, 2020, 14 (01)
  • [44] Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study
    Li, Ya-Jun
    Yi, Ping-Yong
    Li, Ji-Wei
    Liu, Xian-Ling
    Tang, Tian
    Zhang, Pei-Ying
    Jiang, Wen-Qi
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [45] The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study
    Li, Jiwei
    Li, Jin
    Zhong, Meizuo
    Zhou, Hui
    Yu, Baohua
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1541 - 1549
  • [46] Clinical-radiomic features predict survival in patients with extranodal nasal-type natural killer/T cell lymphoma
    Wang, Xinyan
    Qu, Xiaoxia
    Xia, Yuwei
    Wei, Liqiang
    Yang, Jing
    Guo, Na
    Zuo, Panli
    Wang, Liang
    Xian, Junfang
    CHINESE JOURNAL OF ACADEMIC RADIOLOGY, 2022, 5 (03) : 200 - 209
  • [47] 18F-FDG PET/CT Plays a Limited Role in Replacing Bone Marrow Biopsy for Newly Diagnosed Advanced-Stage Patients With Extranodal Natural Killer/T-Cell Lymphoma
    Yang, Chunli
    Wu, Wanchun
    Zhou, Huijie
    Zhao, Sha
    Tian, Rong
    Xiang, Maya
    Zou, Liqun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Clinical-radiomic features predict survival in patients with extranodal nasal-type natural killer/T cell lymphoma
    Xinyan Wang
    Xiaoxia Qu
    Yuwei Xia
    Liqiang Wei
    Jing Yang
    Na Guo
    Panli Zuo
    Liang Wang
    Junfang Xian
    Chinese Journal of Academic Radiology, 2022, 5 : 200 - 209
  • [49] Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group database
    Zheng, Xuan
    Qu, Bao-Lin
    Liu, Xin
    Zhong, Qiu-Zi
    Qian, Li-Ting
    Yang, Yong
    Hou, Xiao-Rong
    Qiao, Xue-Ying
    Wang, Hua
    Zhu, Yuan
    Cao, Jian-Zhong
    Wu, Jun-Xin
    Wu, Tao
    Zhu, Su-Yu
    Shi, Mei
    Zhang, Hui-Lai
    Zhang, Xi-Mei
    Su, Hang
    Song, Yu-Qin
    Zhu, Jun
    Zhang, Yu-Jing
    Huang, Hui-Qiang
    Wang, Ying
    Chen, Fan
    Yin, Lin
    He, Xia
    Zhang, Li-Ling
    Li, Ye-Xiong
    Qi, Shu-Nan
    EJHAEM, 2023, 4 (01): : 78 - 89
  • [50] A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
    Xu, Peng-Peng
    Xiong, Jie
    Cheng, Shu
    Zhao, Xia
    Wang, Chao-Fu
    Cai, Gang
    Zhong, Hui-Juan
    Huang, Heng-Ye
    Chen, Jia-Yi
    Zhao, Wei-Li
    EBIOMEDICINE, 2017, 25 : 41 - 49